Early Ectopic Pregnancy Refractory to Methotrexate Treatment: A Case Report

Cureus. 2021 Nov 18;13(11):e19686. doi: 10.7759/cureus.19686. eCollection 2021 Nov.

Abstract

Methotrexate (MTX) is known as a systemic treatment for early ectopic pregnancy with low serum beta-human chorionic gonadotropin (βhCG) levels. Here we present our experience of an unsatisfactory outcome following MTX treatment for early tubal pregnancy. The case is a 39-year-old female with left tubal ectopic pregnancy and a history of one right tubal ectopic pregnancy and an uneventful episode of delivery. In the absence of any contraindications, the patient underwent initial MTX treatment. At first, her serum βhCG level was 1,258 mIU/mL but remained elevated. Then she underwent a second and third dose of MTX. After a month, the serum βhCG level had not declined to within an acceptable range. The ectopic mass was enlarged as determined by transvaginal ultrasonography and hemoperitoneum. A laparoscopic salpingectomy was performed. Early ectopic tubal pregnancy can be managed medically with a high success rate. However, repeat ectopic pregnancy indicates an increased risk of treatment failure to medical treatment, and should be mentioned to the patient when discussing their treatment options.

Keywords: general gynecology; laparoscopic salpingostomy; laparoscopic surgery; methotrexate; ruptured tubal ectopic pregnancy; serum beta hcg; transvaginal ultrasonography; tubal ectopic pregnancy.

Publication types

  • Case Reports